Background--Multiple randomized controlled trials of remote ischemic preconditioning (RIPC) prior to cardiac surgery have failed to demonstrate clinical benefit. The aim of this updated meta-analysis was to evaluate the effect of RIPC on outcomes following cardiac surgery.
T hirty years ago, Murry et al 1 first described ischemic preconditioning (IPC) after observing that anesthetized dogs subjected to prolonged circumflex coronary artery occlusion and reperfusion demonstrated a marked reduction of myocardial infarct size when exposed to 4 brief episodes of ischemia in the circumflex territory separated by 5 minutes of reperfusion prior to the prolonged occlusion. Remote IPC (RIPC) evolved from the same in vivo canine heart model where ischemia-reperfusion injury could be attenuated in the left anterior descending coronary artery distribution after application of occlusion and reperfusion to the circumflex coronary artery. 2 With this finding, Przyklenk et al 2 concluded that protective mediators induced by ischemia could be transferred to distant, "regional" cardiomyocytes. Subsequent studies demonstrated that protection against ischemiareperfusion injury in humans could be extended to distant organs, such as the kidney and brain. 3, 4 The discovery that protection could be conferred by ischemia-reperfusion cycles in distant skeletal muscle elicited invasively by rapid stimulation of the gastrocnemius in rabbits 5 and noninvasively by a tourniquet in humans 6 spurred widespread clinical interest.
Given that cardiac surgery has the potential for ischemia and reperfusion injury to the heart, kidney and brain, [7] [8] [9] RIPC has long been viewed as an attractive approach to mitigate the deleterious clinical consequences of these events. Prior studies have shown that RIPC before cardiac surgery results in reductions in biomarkers of renal and cardiac injury. 10, 11 However, randomized controlled trials (RCTs) of RIPC evaluating clinical cardiovascular and renal outcomes as well as overall mortality have not shown benefit. 12, 13 Many of these trials utilized propofol anesthesia, which has been shown to negatively impact the benefits of RIPC. 14 With the recent publication of the two largest trials of RIPC to date, 15, 16 we performed an updated meta-analysis of RCTs to better evaluate the clinical merit of this intervention.
Methods

Study Selection
A systematic search of published studies in any language in the PubMed, Cochrane, EMBASE, and Web of Science databases from 1970 to December 13, 2015 , was performed independently by two authors (V.P. and I.B.). Search terms included remote ischemic preconditioning, cardiac surgery, kidney injury, and renal failure, as well as combinations of these terms. A filter for RCTs was used. Bibliographies of retrieved articles and prior reviews on the subject were searched for other relevant studies.
For inclusion, studies were required to be prospective randomized trials of preoperative RIPC or a sham procedure in patients undergoing cardiac surgery performed on cardiopulmonary bypass. In addition, studies had to report at least one clinical end point of interest as an outcome and enroll more than 50 patients. Patient characteristics, study design, and outcomes were systematically reviewed and recorded independently by 3 authors (B.P., I.B., and V.P.). Disagreements were resolved by consensus.
The methodological quality of each trial was evaluated using standard criteria: method of randomization; allocation concealment; patient, investigator, and outcome assessor blinding; selective outcome reporting; incomplete outcome ascertainment; and other potential sources of bias as recommended by the Cochrane Collaboration. 17 The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) approach for evaluating RCTs was applied. 18 The following clinical end points were analyzed: all-cause mortality, acute kidney injury (AKI), myocardial infarction (MI), cerebrovascular accident (CVA), hospital length of stay (LOS), and intensive care unit (ICU) LOS. Discrete working definitions of AKI were reclassified as stage I, II, or III based on previous definitions described by the Acute Kidney Injury Advisory Group. 19 Other end point definitions were those used in the individual trials and are summarized in Table 1 .
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Statistical Analysis
Because patient-level data from each trial were not available, a meta-analysis of summary statistics from individual trials was performed. Data from each trial were analyzed on an intention-to-treat basis according to the recommendations of the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. 34 Trial results for each end point were summarized with risk ratios (RRs) and standardized mean differences as the measures of effect. RRs were employed because accurate time-to-event data were not available in all trials. Summary RRs or standardized mean differences and 95% CIs were calculated using a random-effects model for combining results across studies, which incorporates between-and within-study variance and provides a more conservative summary. A randomeffects model was preferred because heterogeneity across patient characteristics and clinical trial design would be unlikely to result in a consistent treatment effect across trials. 35 When no events were observed within a treatment group, a 0.5 correction factor was added to all values of that end point for calculation of the RR and its variance. 36, 37 To determine whether there was heterogeneity between individual trials, we assessed the Q statistic (a weighted index of effect estimate differences across studies assuming a v value quantifies heterogeneity on a scale of 0% to 100% and represents the extent of inconsistency among trial results rather than a sampling error independent of the number of studies, an I 2 of ≥75% was considered representative of high heterogeneity. 38 To assess for publication bias, funnel plots were evaluated by visual inspection and confirmed by Egger's test. 39 If analysis yielded plot asymmetry, Duval and Tweedie's trim and fill method, a quantitative assessment of publication bias, was performed. 40 Heterogeneity was explored in subgroup analyses by study quality (high versus low), intraoperative propofol use, additive Table 1 . European System for Cardiac Operative Risk Evaluation (EuroSCORE), and preoperative potassium-ATP (K-ATP) antagonist use. Unless an anesthetic regimen without propofol was detailed, it was assumed that propofol was administered. In the event of protocol ambiguity, primary authors were contacted for clarification. In trials that did not exclude diabetic patients, it was assumed that K-ATP antagonists were used unless specifically prohibited preoperatively. Sensitivity analyses were performed for each outcome to determine whether any single study disproportionately influenced the pooled estimate by excluding individual trials one at a time and recalculating the combined RR or standardized mean difference for the remaining studies. P<0.05 was considered statistically significant and all tests were 2-sided. Statistical analyses were performed with Comprehensive Meta-Analysis (version 2) software (Biostat, Englewood, NJ).
Results
Literature Search
The electronic search yielded 833 citations that were screened by reviewing the title or abstract with subsequent removal of duplicates. Of these, 45 articles were reviewed in full and 21 studies were included for analysis ( Figure 1) . Characteristics of the studies are listed in Table 2 . Eight studies tested RIPC in patients undergoing isolated coronary artery bypass grafting (CABG), 12, 20, 21, 23, 26, 29, 31, 41 four studies in patients undergoing isolated valve surgery, 22, 24, 27, 33 and the remaining 9 in patients undergoing any cardiac surgery.* One study included additional perconditioning, the application of short periods of ischemia and reperfusion at a distant site delivered during target organ ischemia; only data from the preconditioning intervention and the sham procedure were included. 22 Of the 5262 patients included in the analysis, 2624 were randomized to RIPC and 2638 were randomized to a sham procedure. Baseline characteristics of the study populations showed that most patients were men (72.6%). The mean or median ages of patients ranged from 42.3 to 76.3 years. The majority of studies were double-blinded, randomized, and had adequate descriptions of patient attrition. Study quality is summarized in Table 3 .
Quantitative Outcomes
Of the 188 deaths in the 4210 randomized patients undergoing cardiac surgery, 96 deaths occurred in the 2098 patients (4.6%) randomized to RIPC, whereas 92 deaths Figure 2F ). Summarized quantitative data for the entire sample can be seen in Table 3 .
Subgroup Analyses, Sensitivity Analyses, and Publication Bias
Subgroup analysis showed no differences in outcomes when compared by the use of K-ATP antagonists (results not shown). In the subgroup of studies of patients who did not receive propofol, we observed that most of these patients were men (60.3%) and the mean or median age ranged from 57.0 to 70.6 years. (Figure 3 ). Summarized quantitative data for these subgroups can be seen in Table 4 . There was no significant interaction between the two subgroups (P=0.098). Additionally, there were no differences in the effect of RIPC on development of stage I, II, or III AKI, and there was no difference in the effect of RIPC on the development of severe AKI, defined as stage II or III AKI (results not shown). 
Figure 1. Study selection. Flow diagram depicts study selection for inclusion in the meta-analysis according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses. 34 RIPC indicates remote ischemic preconditioning. Sensitivity analyses showed no significant differences in outcomes when results were compared by study quality (high versus low), type of surgery performed (CABG, valve, or mixed), severity of illness (based on additive Euro-SCORE), or duration or site of RIPC (results not shown). Visual inspection of the funnel plots suggested possible publication bias (Figure 4 ). This was further analyzed using the trim and fill method. The RR of AKI of 0.839 (95% CI, 0.702-1.001) was unchanged by the trim and fill method, suggesting no publication bias. This was confirmed by the Egger's test, which indicated lack of publication bias (P=0.055).
In addition, sensitivity analyses to assess potential effects of qualitative differences on study design and patient selection showed that exclusion of any one trial from analysis of mortality, AKI, MI, CVA, ICU LOS, and hospital LOS did not change the overall findings (data not shown).
Discussion
In this meta-analysis of 5262 patients undergoing RIPC for cardiac surgery with cardiopulmonary bypass, we found that RIPC conferred no clinical benefit. The intervention failed to reduce the incidence of all-cause mortality, MI, CVA, and ICU or hospital LOS. There was a strong trend towards reduction of AKI in patients who underwent RIPC.
Previous meta-analyses have also failed to demonstrate clinical benefit of RIPC. 42, 43 However, two aspects of this meta-analysis differentiate it from prior studies. First, this analysis includes two recent, large, high-quality RCTs of RIPC in patients undergoing cardiac surgery not included in previous meta-analyses. 15, 16 The inclusion of these trials increased the study population 2-fold. Second, as far as we are aware, this is the first meta-analysis to evaluate outcomes as a function of propofol and K-ATP antagonist use. Although the mechanisms of RIPC have not been fully elucidated, many believe there are components of both humoral and sensory-neuronal pathways that confer organ protection. 44 The neuronal pathway was first described by Jones et al, 45 who demonstrated that myocardial protection could be produced through activation of sensory C fibers by an abdominal incision in mice. Furthermore, transection of the spinal cord and blockade of sensory C fibers by lidocaine investigators have suggested propofol itself may be protective and any incremental benefits of RIPC are too small to be detected. 47 Our analysis is congruent with these theories, as we observed a highly significant reduction in AKI in the subgroup of patients who did not receive propofol, despite no benefit in the overall cohort. In addition to the neuronal pathway, humoral-mediated pathways have also been described. After Huffman et al 48 demonstrated that transfer of serum from preconditioned to recipient rats prior to an induced MI conferred cardiac protection, the mediators of this pathway were explored. Adenosine and bradykinin, among other mediators, have been shown to induce preconditioning of myocytes, thought to be via the activation of the K-ATP channel pathway. 44, 49, 50 Loukogeorgakis et al 51 implicated the K-ATP pathway in IPC-mediated endothelial protection by demonstrating abolition of the protective effect after administration of glibenclamide, a K-ATP antagonist. In our subgroup analysis, after removal of studies that included patients treated with K-ATP antagonists, clinical benefit of RIPC was still not observed.
Study Limitations
The results of this meta-analysis should be interpreted with consideration of its limitations. First, the majority of trials included in the review were single-center studies with varying inclusion and exclusion criteria. Second, definitions for outcomes and duration of follow-up differed between included trials. Third, because we assumed that all patients in a given trial either did or did not receive propofol, a portion of patients within individual trials may have been miscategorized. Additionally, variability in RIPC protocols may have led to heterogeneity in the analysis. Finally, data were extracted only from RCTs and may not be representative of patients treated in usual practice.
Conclusions
RIPC does not prevent morbidity or mortality in patients undergoing cardiac surgery with cardiopulmonary bypass. In the subgroup of studies in which propofol was not used, a reduction in AKI was seen, suggesting that propofol may interact with the protective effects of RIPC. To evaluate the independent effect of RIPC on outcomes, future studies on RIPC should be performed in the absence of propofol anesthesia. Figure 4 . Assessment of publication bias. This funnel plot is a plot of a measure of study size on the vertical axis as a function of effect size on the horizontal axis for acute kidney injury. Large studies appear toward the top of the graph and tend to cluster near the mean effect size. Smaller studies appear toward the bottom of the graph and (since there is more sampling variation in effect size estimates in the smaller studies) will be dispersed across a range of values. In the absence of publication bias, the studies, represented by circles, are distributed symmetrically about the combined effect size. The dashed diamond appearing below the x axis represents the summary effect.
